Intra-Cellular Slumps to 2-Year Low as Schizophrenia Study Fails

Updated on
  • Drug was in the third and final stage of testing for approval
  • Shares down as much as 65%, biggest intraday drop ever

Intra-Cellular Therapies Inc. shares plummeted to their lowest level in almost two years after its lead drug, an experimental pill for treating schizophrenia, failed to help patients in a key late-stage study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.